Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Antigens, CD19
/ immunology
Child
Child, Preschool
Female
Humans
Immunotherapy, Adoptive
/ adverse effects
Male
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ diagnosis
Prognosis
Receptors, Antigen, T-Cell
/ genetics
Receptors, Chimeric Antigen
Recurrence
T-Lymphocytes
/ immunology
Treatment Outcome
B-ALL
CAR-T
CD19
chimeric antigen receptor
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
15
01
2019
revised:
31
03
2019
accepted:
22
08
2019
pubmed:
30
8
2019
medline:
14
1
2020
entrez:
30
8
2019
Statut:
ppublish
Résumé
Ninety percent of relapse/refractory B-cell acute lymphatic leukemia (R/R B-ALL) patients can achieve complete remission (CR) after CD19-targeting chimeric antigen receptor T (CAR-T) cell therapy. However, around 50% of them relapse in 1 year. Persistent CAR-T cell engraftment is considered as the key to remain durable remission. Here, we initiated a phase I study to treat 10 pediatric B-ALL patients using a CD19-targeted second generation CAR with a 4-1BB intracellular costimulatory domain. All patients received a standard fludarabine and cyclophosphamide (FC) preconditioning regiment, followed by a CAR-T infusion with a median number of 0.5 (0.3-1.58) × 10
Identifiants
pubmed: 31465532
doi: 10.1002/hon.2672
pmc: PMC6973049
doi:
Substances chimiques
Antigens, CD19
0
Receptors, Antigen, T-Cell
0
Receptors, Chimeric Antigen
0
Types de publication
Clinical Trial, Phase I
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
601-608Subventions
Organisme : Natural Science Foundation of Hebei Province
ID : H2019B72003
Organisme : Hebei Senlang Bio. Co. Ltd
Informations de copyright
©2019 John Wiley & Sons, Ltd.
Références
Nat Rev Clin Oncol. 2015 Jun;12(6):344-57
pubmed: 25781572
JCI Insight. 2018 May 17;3(10):
pubmed: 29769444
Sci Transl Med. 2013 Mar 20;5(177):177ra38
pubmed: 23515080
J Clin Invest. 2016 Jun 1;126(6):2123-38
pubmed: 27111235
Nat Med. 2018 Jan;24(1):20-28
pubmed: 29155426
J Hematol Oncol. 2018 Mar 2;11(1):35
pubmed: 29499750
Nat Med. 2018 May;24(5):563-571
pubmed: 29713085
Hematol Oncol. 2019 Dec;37(5):601-608
pubmed: 31465532
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
Blood. 2013 Dec 12;122(25):4129-39
pubmed: 24055823
Int J Hematol. 2014 Apr;99(4):361-71
pubmed: 24311149
J Clin Invest. 2016 Oct 3;126(10):3814-3826
pubmed: 27571406
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Lancet. 2015 Feb 7;385(9967):517-528
pubmed: 25319501
Sci Transl Med. 2011 Aug 10;3(95):95ra73
pubmed: 21832238
Leukemia. 2016 Feb;30(2):492-500
pubmed: 26369987
J Immunother. 2012 Nov-Dec;35(9):689-701
pubmed: 23090078
Nature. 2018 Jun;558(7709):307-312
pubmed: 29849141
J Clin Invest. 2019 Mar 12;129(5):2123-2132
pubmed: 30860496
N Engl J Med. 2013 Apr 18;368(16):1509-1518
pubmed: 23527958